Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomasENSINGER, Christian; PROMMEGGER, Rupert; KENDLER, Dorotha et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2349-2353, issn 0250-7005, 5 p.Article

HER2/NEU-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapyBUCHHOLZ, Thomas A; HUANG, Eugene H; VALERO, Vicente et al.International journal of radiation oncology, biology, physics. 2004, Vol 59, Num 5, pp 1337-1342, issn 0360-3016, 6 p.Article

Engineering of Escherichia coli for Targeted Delivery of Transgenes to HER2/neu-Positive Tumor CellsCHANG, Chih-Hsiang; CHENG, Wei-Jou; CHEN, Shan-Yu et al.Biotechnology and bioengineering. 2011, Vol 108, Num 7, pp 1662-1672, issn 0006-3592, 11 p.Article

Site-specifically conjugated anti-HER2 Affibody® molecules as one-step reagents for target expression analyses on cells and xenograft samplesLUNDBERG, Emma; HÖIDEN-GUTHENBERG, Ingmarie; LARSSON, Barbro et al.Journal of immunological methods. 2007, Vol 319, Num 1-2, pp 53-63, issn 0022-1759, 11 p.Article

Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalingLÖBKE, Christian; LAIBLE, Mark; RAPPL, Claudia et al.Proteomics (Weinheim. Print). 2008, Vol 8, Num 8, pp 1586-1594, issn 1615-9853, 9 p.Article

Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinomaSMORLESI, Arianna; PAPALINI, Francesca; AMICI, Augusto et al.Vaccine. 2006, Vol 24, Num 11, pp 1766-1775, issn 0264-410X, 10 p.Article

Amplification of the HER-2/neu protooncogene in human endocrine tumors. DiscussionEVERS, M; RADY, P. L; DEMEURE, M et al.Surgery. 1992, Vol 112, Num 2, pp 211-218, issn 0039-6060Conference Paper

Quantification in histopathology- : Can magnetic particles help?MITCHELS, John; HAWKINS, Peter; LUXTON, Richard et al.Journal of magnetism and magnetic materials. 2007, Vol 311, Num 1, pp 264-268, issn 0304-8853, 5 p.Conference Paper

Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometrySCHOENHERR, Regine M; WHITEAKER, Jeffrey R; LEI ZHAO et al.Proteomics (Weinheim. Print). 2012, Vol 12, Num 8, pp 1253-1260, issn 1615-9853, 8 p.Article

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabTODESCHINI, P; COCCO, E; RATNER, E et al.British journal of cancer. 2011, Vol 105, Num 8, pp 1176-1182, issn 0007-0920, 7 p.Article

Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic miceJACQUEMART, Isabelle C; SPRINGS, Alison E. B; CHEN, Wen Y et al.International journal of oncology. 2009, Vol 34, Num 2, pp 517-528, issn 1019-6439, 12 p.Article

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissueLINDEMANN, K; RESAU, J; HARBECK, N et al.Histopathology. 2007, Vol 51, Num 1, pp 54-62, issn 0309-0167, 9 p.Article

Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathwayMAKINO, Keishi; DAY, Chi-Ping; WANG, Shao-Chun et al.Oncogene (Basingstoke). 2004, Vol 23, Num 21, pp 3883-3887, issn 0950-9232, 5 p.Article

Prognostic factors in human primary breast cancer : comparison of c-myc and HER2/neu amplificationBERNS, E. M. J. J; FOEKENS, J. A; VAN PUTTEN, W. L. J et al.Journal of steroid biochemistry and molecular biology. 1992, Vol 43, Num 1-3, pp 13-19, issn 0960-0760Conference Paper

HER2/neu as a Potential Target for Immunotherapy in Gynecologic CarcinosarcomasGUZZO, Federica; BELLONE, Stefania; SCHWARTZ, Peter E et al.International journal of gynecological pathology. 2012, Vol 31, Num 3, pp 211-221, issn 0277-1691, 11 p.Article

Immunohistochemical and molecular subtypes of breast cancer in NigeriaADEBAMOWO, Clement A; FAMOOTO, Ayotunde; OGUNDIRAN, Temidayo O et al.Breast cancer research and treatment. 2008, Vol 110, Num 1, pp 183-188, issn 0167-6806, 6 p.Article

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technologyDEHQANZADA, Zia A; STORRER, Catherine E; HUEMAN, Matthew T et al.Oncology reports. 2007, Vol 17, Num 3, pp 687-694, issn 1021-335X, 8 p.Article

Mucin-rich variant of salivary duct carcinoma: A clinicopathologic and immunohistochemical study of four casesSIMPSON, Roderick H. W; PRASAD, Anil R; LEWIS, Jean E et al.The American journal of surgical pathology. 2003, Vol 27, Num 8, pp 1070-1079, issn 0147-5185, 10 p.Article

Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasmsSEIDMAN, J. D; FRISMAN, D. M; NORRIS, H. J et al.Cancer. 1992, Vol 70, Num 12, pp 2857-2860, issn 0008-543XArticle

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative statusMURPHY, Niamh C; BIANKIN, Andrew V; MOREY, Adrienne L et al.International journal of cancer (Print). 2010, Vol 126, Num 6, pp 1445-1453, issn 0020-7136, 9 p.Article

The oncogene HER2 : its signaling and transforming functions and its role in human cancer pathogenesisMOASSER, M. M.Oncogene (Basingstoke). 2007, Vol 26, Num 45, pp 6469-6487, issn 0950-9232, 19 p.Article

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsDANIELS, Tracy R; LEUCHTER, Richard K; QUINTERO, Rafaela et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 7, pp 991-1003, issn 0340-7004, 13 p.Article

Fixation Time Does Not Affect Expression of HER2/neu: A Pilot StudyIBARRA, Julio A; ROGERS, Lowell W.American journal of clinical pathology. 2010, Vol 134, Num 4, pp 594-596, issn 0002-9173, 3 p.Article

HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimensLESNIKOVA, Iana; LIDANG, Marianne; HAMILTON-DUTOIT, Stephen et al.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2009, Vol 117, Num 10, pp 737-745, issn 0903-4641, 9 p.Article

Metaplastic breast carcinoma : clinical-pathologic characteristics and HER2/neu expressionBARNES, P. J; BOUTILIER, R; CHIASSON, D et al.Breast cancer research and treatment. 2005, Vol 91, Num 2, pp 173-178, issn 0167-6806, 6 p.Article